Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8⁺ large granular lymphocyte leukemia

Keyphrases

• CD8+ 100%
• Cytotoxic T Cells 100%
• Variable Expression 100%
• Therapeutic Implications 100%
• Large Granular Lymphocyte Leukemia 100%
• CD52 100%
• Alemtuzumab 62%
• Cytotoxic T Lymphocytes 37%
• GPI-anchored Protein (GPI-AP) 37%
• Large Granular Lymphocyte 25%
• Clinical Trials 12%
• Immunosuppression 12%
• T Cell Receptor 12%
• Lymphoid Malignancies 12%
• Monoclonal Antibody 12%
• Treatment Options 12%
• Lack of Response 12%
• Platelets 12%
• Treatment Outcome 12%
• Remission 12%
• Treatment Regimen 12%
• Neutropenia 12%
• Healthy Controls 12%
• Highly Effective 12%
• Multiple Treatments 12%
• Current Treatment 12%
• Salvage Therapy 12%
• Flow Cytometry 12%
• Control Population 12%
• Overall Response Rate 12%
• Red Blood Cell Transfusion 12%
• Survival Benefit 12%
• Cytopenia 12%
• CD55 12%
• CD59 12%
• T Cell Clonal Expansion 12%
• T-cell Large Granular Lymphocytic Leukemia 12%
• Serial Monitoring 12%
• Refractory Cytopenia 12%
• Clonal Proliferation 12%
• CD8+ T 12%
• Transfusion Independence 12%

Medicine and Dentistry

• Cytotoxic T-Cell 100%
• Large Granular Lymphocytic Leukemia 100%
• CD8 Antigen 100%
• Alemtuzumab 100%
• Glycosylphosphatidylinositol 60%
• T Cell 40%
• Large Granular Lymphocyte 40%
• Cytopenia 40%
• Clinical Trial 20%
• Platelet 20%
• T Lymphocyte Receptor 20%
• Immunosuppressive Treatment 20%
• Lymphoma 20%
• Population Dynamics 20%
• Neutropenia 20%
• Salvage Therapy 20%
• Flow Cytometry 20%
• Erythrocyte Transfusion 20%
• Decay Accelerating Factor 20%
• Monoclonal Antibody 20%

Immunology and Microbiology

• Cytotoxic T Cell 100%
• Large Granular Lymphocyte 100%
• CD8 100%
• Alemtuzumab 100%
• Glycophosphatidylinositol 60%
• T Cell 40%
• T Cell Receptor 20%
• Platelet 20%
• Immunosuppression 20%
• Cytotoxic T-Cell 20%
• Hemocyte 20%
• Decay-Accelerating Factor 20%
• Monoclonal Antibody 20%
• Population Dynamics 20%
• CD59 20%